Substance / Medication

Crotamiton

Overview

Active Ingredient
crotamiton
RxNorm CUI
21766

Indications

INDICATIONS AND USAGE: Sarcoptes scabiei For eradication of scabies () and for symptomatic treatment of pruritic skin.

Labeler: Trifluent Pharma, LLCUpdated: 2025-06-02T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

CONTRAINDICATIONS: Pruradik lotion should not be applied topically to patients who develop a sensitivity or are allergic to it or who manifest a primary irritation response to topical medications.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

5 trials linked to this intervention

5
Total Trials
2
Recruiting
2
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Failure of scabies treatment: a systematic review and meta-analysis.
Mbuagbaw Lawrence, Sadeghirad Behnam, Morgan Rebecca L et al. · Br J Dermatol · 2024
PMID: 37625798Meta-Analysis
A systematic review of immunosuppressive risk factors and comorbidities associated with the development of crusted scabies.
Bergamin Gianni, Hudson Joshua, Currie Bart J et al. · Int J Infect Dis · 2024
PMID: 38570134Meta-Analysis
Risk factors for scabies in hospital: a systematic review.
Kim Dong-Hee, Kim Yujin, Yun Sook Young et al. · BMC Infect Dis · 2024
PMID: 38575893Meta-AnalysisFull text (PMC)
Global prevalence and predictors of scabies among prisoners: systematic review and meta-analysis.
Delie Amare Mebrat, Bogale Eyob Ketema, Anagaw Tadele Fentabel et al. · BMC Public Health · 2024
PMID: 39010037Meta-AnalysisFull text (PMC)
Systematic review of the evidence for treatment and management of common skin conditions in resource-limited settings: An update.
Amgarth-Duff Ingrid, Thomas Hannah, Ricciardo Bernadette M et al. · Trop Med Int Health · 2024
PMID: 39396816Meta-Analysis
Prevalence and determinants of scabies: A global systematic review and meta-analysis.
Gupta Saptorshi, Thornley Simon, Morris Arthur et al. · Trop Med Int Health · 2024
PMID: 39575757Meta-AnalysisFull text (PMC)
Prevalence of scabies worldwide-An updated systematic literature review in 2022.
Schneider S, Wu J, Tizek L et al. · J Eur Acad Dermatol Venereol · 2023
PMID: 37147907Meta-Analysis
Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis.
Lake Susanna J, Kaldor John M, Hardy Myra et al. · Clin Infect Dis · 2022
PMID: 35088849Meta-AnalysisFull text (PMC)
Treatment of scabies, permethrin 5% cream vs. crotamiton 10% cream.
Pourhasan Abolfazl, Goldust Mohamad, Rezaee Elham · Ann Parasitol · 2013
PMID: 24881286RCT
Percutaneous absorption of crotamiton in man following single and multiple dosing.
Dika E, Tosti A, Goldovsky M et al. · Cutan Ocul Toxicol · 2006
PMID: 16980246Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Crotamiton (substance)
SNOMED CT
387515007
UMLS CUI
C0056519
RxNorm CUI
21766
Labeler
Trifluent Pharma, LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
5
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.